DPP‐IV inhibitors are already used mainly as adjuvants in the treatment of diabetes, and the search for PTP1B modulators, such as Vicenin‐2, has attracted increasing attention as a therapeutic target in the treatment of diabetes and obesity (Islam et al., 2014; Liu, Mathieu, et al., 2022). Here, PTPN1 is linked to Obesity.